A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic LeukemiaHannah Goulart, Nitin Jain, Naveen Pemmaraju et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 8
Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 StudyHannah Goulart, Hagop Kantarjian, Elias Jabbour et al.|Blood|2025Cited by 2